Fampridine and working memory in mild to moderate depression
About this title
Read the official source — NCT06751784Understand this study
Who could participate?
Listed age limits: 18 years to 55 years.
What will I do during this study?
In this crossover study, you receive fampridine and placebo (an inactive comparison treatment) during separate 7.5-day periods, with tablets taken twice daily. The periods are separated by a washout interval of at least 6.5 days, which may extend to 28 days depending on scheduling.
- Listed locations
- BaselSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 38
- Sponsor
- University of Basel
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Switzerland
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT06751784
- Official title
Show the full official title
Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Mild to Moderate Depression
Recruitment & locations
Basel
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Basel, a university.
Does this study involve medication?
Yes. The study involves medication, including Fampridine SR.
Who can participate?
Listed age limits: 18 years to 55 years.
Is this study still recruiting?
The registry lists this study as recruiting.
